Famotidine (Mk-208) in the treatment of gastric ulcer: Results of a multicenter double-blind controlled study

P. Paoluzi; A. Torsoli; G. Bianchi Porro; M. Lazzaroni; L. Barbara; R. Corinaldesi; A. Blasi; A. Mangiameli; L. Carratelli; R. Cheli; E. Bovero; P. R. Dal Monte; N. D’imperio; A. Francavilla; F. Doronzo; G. Mazzacca; F. Sabbatini; G. Verme; V. Ponti; V. Speranza; E. Lezoche; A. Buglioni; F. Carotenuto; P. F. Matarazzo

doi:10.1159/000199260

Famotidine (Mk-208) in the treatment of gastric ulcer: Results of a multicenter double-blind controlled study

P. Paoluzi, A. Torsoli, G. Bianchi Porro, M. Lazzaroni, L. Barbara, R. Corinaldesi, A. Blasi, A. Mangiameli, L. Carratelli, R. Cheli, E. Bovero, P. R. Dal Monte, N. D’imperio, A. Francavilla, F. Doronzo, G. Mazzacca, F. Sabbatini, G. Verme, V. Ponti, V. SperanzaE. Lezoche, A. Buglioni, F. Carotenuto, P. F. Matarazzo

Ente Ospedaliero Specializzato in Gastroenterologia "Saverio de Bellis"

Research output: Contribution to journal › Article › peer-review

Abstract

The aim of the present investigation was to study the efficacy and safety of famotidine (MK-208). a new. potent, histamine H₂ receptor antagonist, in promoting the healing of active gastric ulcer when compared to placebo. Of the 71 patients who took part in this multicenter double-blind study in Italy. 37 were administered famotidine 40 mg once daily and 34 placebo. Treatment duration was for up to 8 weeks, and endoscopic and clinical studies were performed at onset and week 4 and, if necessary, at weeks 6 and 8. All patients were carefully evaluated at regular intervals for adverse drug reactions by clinical and laboratory examinations. By the end of the study, 97% of the ulcers were healed in the famotidine group compared to 66% in the placebo group (p

Original language	English
Pages (from-to)	38-44
Number of pages	7
Journal	Digestion
Volume	32
DOIs	https://doi.org/10.1159/000199260
Publication status	Published - 1985

Keywords

Famotidine
Gastric ulcer
Placebo

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1159/000199260

Fingerprint Dive into the research topics of 'Famotidine (Mk-208) in the treatment of gastric ulcer: Results of a multicenter double-blind controlled study'. Together they form a unique fingerprint.

Cite this

Paoluzi, P., Torsoli, A., Porro, G. B., Lazzaroni, M., Barbara, L., Corinaldesi, R., Blasi, A., Mangiameli, A., Carratelli, L., Cheli, R., Bovero, E., Dal Monte, P. R., D’imperio, N., Francavilla, A., Doronzo, F., Mazzacca, G., Sabbatini, F., Verme, G., Ponti, V., ... Matarazzo, P. F. (1985). Famotidine (Mk-208) in the treatment of gastric ulcer: Results of a multicenter double-blind controlled study. Digestion, 32, 38-44. https://doi.org/10.1159/000199260

Famotidine (Mk-208) in the treatment of gastric ulcer : Results of a multicenter double-blind controlled study. / Paoluzi, P.; Torsoli, A.; Porro, G. Bianchi; Lazzaroni, M.; Barbara, L.; Corinaldesi, R.; Blasi, A.; Mangiameli, A.; Carratelli, L.; Cheli, R.; Bovero, E.; Dal Monte, P. R.; D’imperio, N.; Francavilla, A.; Doronzo, F.; Mazzacca, G.; Sabbatini, F.; Verme, G.; Ponti, V.; Speranza, V.; Lezoche, E.; Buglioni, A.; Carotenuto, F.; Matarazzo, P. F.

In: Digestion, Vol. 32, 1985, p. 38-44.

Research output: Contribution to journal › Article › peer-review

Paoluzi, P, Torsoli, A, Porro, GB, Lazzaroni, M, Barbara, L, Corinaldesi, R, Blasi, A, Mangiameli, A, Carratelli, L, Cheli, R, Bovero, E, Dal Monte, PR, D’imperio, N, Francavilla, A, Doronzo, F, Mazzacca, G, Sabbatini, F, Verme, G, Ponti, V, Speranza, V, Lezoche, E, Buglioni, A, Carotenuto, F & Matarazzo, PF 1985, 'Famotidine (Mk-208) in the treatment of gastric ulcer: Results of a multicenter double-blind controlled study', Digestion, vol. 32, pp. 38-44. https://doi.org/10.1159/000199260

Paoluzi, P. ; Torsoli, A. ; Porro, G. Bianchi ; Lazzaroni, M. ; Barbara, L. ; Corinaldesi, R. ; Blasi, A. ; Mangiameli, A. ; Carratelli, L. ; Cheli, R. ; Bovero, E. ; Dal Monte, P. R. ; D’imperio, N. ; Francavilla, A. ; Doronzo, F. ; Mazzacca, G. ; Sabbatini, F. ; Verme, G. ; Ponti, V. ; Speranza, V. ; Lezoche, E. ; Buglioni, A. ; Carotenuto, F. ; Matarazzo, P. F. / Famotidine (Mk-208) in the treatment of gastric ulcer : Results of a multicenter double-blind controlled study. In: Digestion. 1985 ; Vol. 32. pp. 38-44.

@article{3b9317bf6e7848c0a9bf159e1b174c04,

title = "Famotidine (Mk-208) in the treatment of gastric ulcer: Results of a multicenter double-blind controlled study",

abstract = "The aim of the present investigation was to study the efficacy and safety of famotidine (MK-208). a new. potent, histamine H2 receptor antagonist, in promoting the healing of active gastric ulcer when compared to placebo. Of the 71 patients who took part in this multicenter double-blind study in Italy. 37 were administered famotidine 40 mg once daily and 34 placebo. Treatment duration was for up to 8 weeks, and endoscopic and clinical studies were performed at onset and week 4 and, if necessary, at weeks 6 and 8. All patients were carefully evaluated at regular intervals for adverse drug reactions by clinical and laboratory examinations. By the end of the study, 97% of the ulcers were healed in the famotidine group compared to 66% in the placebo group (p",

keywords = "Famotidine, Gastric ulcer, Placebo",

author = "P. Paoluzi and A. Torsoli and Porro, {G. Bianchi} and M. Lazzaroni and L. Barbara and R. Corinaldesi and A. Blasi and A. Mangiameli and L. Carratelli and R. Cheli and E. Bovero and {Dal Monte}, {P. R.} and N. D{\textquoteright}imperio and A. Francavilla and F. Doronzo and G. Mazzacca and F. Sabbatini and G. Verme and V. Ponti and V. Speranza and E. Lezoche and A. Buglioni and F. Carotenuto and Matarazzo, {P. F.}",

year = "1985",

doi = "10.1159/000199260",

language = "English",

volume = "32",

pages = "38--44",

journal = "Digestion",

issn = "0012-2823",

publisher = "S. Karger AG",

}

TY - JOUR

T1 - Famotidine (Mk-208) in the treatment of gastric ulcer

T2 - Results of a multicenter double-blind controlled study

AU - Paoluzi, P.

AU - Torsoli, A.

AU - Porro, G. Bianchi

AU - Lazzaroni, M.

AU - Barbara, L.

AU - Corinaldesi, R.

AU - Blasi, A.

AU - Mangiameli, A.

AU - Carratelli, L.

AU - Cheli, R.

AU - Bovero, E.

AU - Dal Monte, P. R.

AU - D’imperio, N.

AU - Francavilla, A.

AU - Doronzo, F.

AU - Mazzacca, G.

AU - Sabbatini, F.

AU - Verme, G.

AU - Ponti, V.

AU - Speranza, V.

AU - Lezoche, E.

AU - Buglioni, A.

AU - Carotenuto, F.

AU - Matarazzo, P. F.

PY - 1985

Y1 - 1985

N2 - The aim of the present investigation was to study the efficacy and safety of famotidine (MK-208). a new. potent, histamine H2 receptor antagonist, in promoting the healing of active gastric ulcer when compared to placebo. Of the 71 patients who took part in this multicenter double-blind study in Italy. 37 were administered famotidine 40 mg once daily and 34 placebo. Treatment duration was for up to 8 weeks, and endoscopic and clinical studies were performed at onset and week 4 and, if necessary, at weeks 6 and 8. All patients were carefully evaluated at regular intervals for adverse drug reactions by clinical and laboratory examinations. By the end of the study, 97% of the ulcers were healed in the famotidine group compared to 66% in the placebo group (p

AB - The aim of the present investigation was to study the efficacy and safety of famotidine (MK-208). a new. potent, histamine H2 receptor antagonist, in promoting the healing of active gastric ulcer when compared to placebo. Of the 71 patients who took part in this multicenter double-blind study in Italy. 37 were administered famotidine 40 mg once daily and 34 placebo. Treatment duration was for up to 8 weeks, and endoscopic and clinical studies were performed at onset and week 4 and, if necessary, at weeks 6 and 8. All patients were carefully evaluated at regular intervals for adverse drug reactions by clinical and laboratory examinations. By the end of the study, 97% of the ulcers were healed in the famotidine group compared to 66% in the placebo group (p

KW - Famotidine

KW - Gastric ulcer

KW - Placebo

UR - http://www.scopus.com/inward/record.url?scp=0022387074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022387074&partnerID=8YFLogxK

U2 - 10.1159/000199260

DO - 10.1159/000199260

M3 - Article

C2 - 2866135

AN - SCOPUS:0022387074

VL - 32

SP - 38

EP - 44

JO - Digestion

JF - Digestion

SN - 0012-2823

ER -